A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01272089

Enrollment

300

Registered

2011-01-07

Start date

2011-05-31

Completion date

2011-12-31

Last updated

2012-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Brief summary

The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study.

Interventions

DRUGOlopatadine Hydrochloride Ophthalmic Solution, 0.2%

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* History (within the past 24 months) of allergic conjunctivitis. * Willing to avoid contact lens wear for each of the study visits, immediately prior to study medication installation and for 10 minutes after installation of study drug. * Contact lens wear should be stable and consistent for 3 months prior to Screening Visit (Day 1). * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Contraindications or hypersensitivity to the use of the study medication or its components. * Inability or unwillingness to follow all study instructions and complete study visits as required. * Subjects with only one sighted eye or not correctable (using ETDRS chart) to 0.6 log MAR or better in both eyes at the Screening Visit. * A known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye). * Ocular trauma within six months prior to Visit 1 in either eye as determined by subject history and/or examination. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame	Description
Overall Patient Satisfaction	Day 7	As assessed by the subject on a questionnaire

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026